Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: jbershad who wrote (1019)	1/8/1998 7:42:00 AM
From: Arthur Radley	Respond to of 2173

OFF TOPIC: For those of you interested in another approach to the diabetes market, take a look at Polymedica(PM). PM is a diabetic testing company that is growing by about 10,000 new clients a month as the result of their national TV campaign. When new Medicare rules start in July their potential customer base will double as Medicare will pay for non-insulin dependent patients that need to test their condition. I have started a thread for PM (The Stock for 1998). Good luck with your interest in AMLN. With the growing numbers that suffer from this condition we desperately need new ways to treat this problem. In my case, it is my dog that has to have two insulin shots each day.

To: jbershad who wrote (1019)	1/8/1998 8:38:00 AM
From: tonyt	Read Replies (1) \| Respond to of 2173

SAN DIEGO, Jan 8 (Reuters) - Amylin Pharmaceuticals Inc said Thursday Marjorie Sennett would step down as senior vice president and chief financial officer for personal reasons. The company has initiated a search for a new CFO, it said in a statement. Sennett, who the company said wants to spend a sabbatical period with her family, will work full time through January and then part time for three months to assist in the transition. Copyright 1998, Reuters News Service